SC
MRNA icon

Savant Capital’s Moderna MRNA Stock Holding History

Savant Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Buy
+7,432
New +$385K ﹤0.01% 1291
2024
Q3 		– Sell
-2,338
Closed -$278K – 1438
2024
Q2 		$278K Sell
2,338
-929
-28% -$118K ﹤0.01% 1008
2024
Q1 		$348K Buy
3,267
+223
+7% +$22.5K ﹤0.01% 850
2023
Q4 		$303K Sell
3,044
-290
-9% -$24.4K ﹤0.01% 701
2023
Q3 		$344K Sell
3,334
-740
-18% -$82.5K 0.01% 614
2023
Q2 		$495K Buy
4,074
+1,703
+72% +$227K 0.01% 510
2023
Q1 		$364K Buy
2,371
+258
+12% +$42.6K 0.01% 545
2022
Q4 		$380K Buy
2,113
+390
+23% +$63.8K 0.01% 410
2022
Q3 		$204K Buy
+1,723
New +$261K 0.01% 513
2022
Q2 		– Sell
-1,306
Closed -$225K – 578
2022
Q1 		$225K Buy
1,306
+132
+11% +$22.2K 0.01% 522
2021
Q4 		$298K Buy
+1,174
New +$343K 0.01% 452

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Savant Capital's MRNA Position: Q2 2026 in Review

Savant Capital opened a new position in Moderna (MRNA) in Q2 2026: 7,432 shares worth $441K. The stake represents ﹤0.01% of the portfolio and ranks #1291 among its holdings. This is a return to the name: Savant Capital previously reported a position in MRNA as recently as Q2 2024.

Savant Capital first reported a position in MRNA in Q4 2021 and has held it in 11 quarters since. The position peaked at $495K in Q2 2023. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Savant Capital held 7,432 shares of Moderna worth $441K as of Q2 2026.
  • Moderna was a new Savant Capital position in Q2 2026.
  • Moderna made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1291 holding.
  • Savant Capital first reported a position in Moderna in Q4 2021 and has held it in 11 quarters since.
  • Savant Capital's Moderna position peaked at $495K in Q2 2023.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.